Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VLA2001 · 4 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| VLA2001 | EXPERIMENTAL | - |
| AZD1222 | ACTIVE_COMPARATOR | \<30 years will receive VLA2001; participants aged ≥30 years will be randomised 2:1 to receive VLA2001 or AZD1222 |
| VLA2001 - adolescent part | EXPERIMENTAL | ≥12 to \< 18 years will be randomized 1:1 to receive VLA2001 or Placebo |
| Placebo | PLACEBO_COMPARATOR | ≥12 to \< 18 years will be randomized 1:1 to receive VLA2001 or Placebo |
| Low Dose: VLA2001 | EXPERIMENTAL | - |
| Medium Dose: VLA2001 | EXPERIMENTAL | - |
| High Dose: VLA2001 | EXPERIMENTAL | - |
| Booster: High Dose: VLA2001 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VLA2001 | BIOLOGICAL | whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide (Wuhan strain) 2 vaccinations 28 days apart Booster Vaccination on Visit B1 |
| AZD1222 | BIOLOGICAL | 2 vaccinations 28 days apart AZD1222 is a recombinant, replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 S surface glycoprotein. |
| VLA2001 - adolescent part | BIOLOGICAL | whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxid 2 vaccinations 28 days apart and with a booster vaccination on day 208. Placebo group will receive VLA2001 on day 208 and following second vaccination 28 days later. |
| Placebo | BIOLOGICAL | 2 vaccinations 28 days apart with placebo (PBS buffer based on Dulbecco's PBS media formulation without Calcium and Magnesium ) |
Inclusion Criteria: 1. All participants must have read, understood, and signed the informed consent form (ICF). 2. Participants of either gender aged 56 years or older at screening. 3. Medically stable such that, according to the judgment of the investigator, hospitalization within the study period...
VLA2001 is an investigational vaccine candidate for SARS-CoV-2 infection, the virus that causes COVID-19. It is being developed to prevent SARS-CoV-2 virus infection in healthy individuals. The vaccine is currently in clinical development and has not been approved by regulatory authorities.
VLA2001 is being developed by Valneva SE, a biopharmaceutical company traded on the stock exchange under the ticker symbol VALN. Valneva is conducting clinical trials to evaluate the safety and immunogenicity of this vaccine candidate against SARS-CoV-2.
VLA2001 is in Phase 2 clinical development. It has completed Phase 1 and Phase 3 trials, but the most recent trial listed is a Phase 2 study evaluating the vaccine as a booster. The vaccine remains investigational and is not yet approved for use.
VLA2001 has been studied in several completed clinical trials, including NCT04671017, a Phase 1 dose-finding study in the United Kingdom; NCT04864561, a Phase 3 trial comparing VLA2001 to AZD1222; NCT04956224, a Phase 3 study in adults aged 56 and older; and NCT05364242, a Phase 2 booster study.
VLA2001 is an inactivated, adjuvanted SARS-CoV-2 virus vaccine candidate. It contains whole virus particles that have been inactivated so they cannot cause disease, but can stimulate the immune system to produce a protective response against the virus. The vaccine is designed to induce immunity against SARS-CoV-2.
VLA2001 is a COVID-19 vaccine candidate specifically designed to prevent SARS-CoV-2 virus infection. It is an inactivated whole-virus vaccine, which is a different approach compared to mRNA vaccines. However, it is not yet approved and remains in clinical development.